
Get exclusive money-saving offers and guides
Straight to your inbox
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Mediland Pharm Limited is a household & personal products business based in Australia. Mediland Pharm shares (MPH) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Mediland Pharm has a trailing 12-month revenue of around $23.3 million.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | $0.043 - $0.175 |
---|---|
50-day moving average | $0.053 |
200-day moving average | $0.0916 |
Target price | N/A |
PE ratio | 24 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $0.015 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing Mediland Pharm stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Mediland Pharm 's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Mediland Pharm 's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 24x. In other words, Mediland Pharm shares trade at around 24x recent earnings.
That's relatively low compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Mediland Pharm 's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $654,369 (£363,069).
The EBITDA is a measure of a Mediland Pharm 's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | $23.3 million |
---|---|
Gross profit TTM | $17.8 million |
Return on assets TTM | -14.53% |
Return on equity TTM | -46.84% |
Profit margin | -21.93% |
Book value | 0.028 |
Market capitalisation | $13.4 million |
TTM: trailing 12 months
We're not expecting Mediland Pharm to pay a dividend over the next 12 months.
Mediland Pharm Limited, together with subsidiaries, engages in the retail sale of health, beauty, and wellness products in Australia and New Zealand. The company's stores also offers luxury products, such as opal and pink diamond jewelry pieces, souvenirs and gifts, luxurious bedding and rugs. It operates through one direct store in Australia; one store in Auckland, New Zealand; six franchise shops in China; three WeChat accounts; and four e-commerce platforms. The company was founded in 2002 and is headquartered in Sydney, Australia.
Robinhood is set to go public as soon as June. Here's what you need to do to buy in from Australia.
We explain everything you need to make your own retro arcade machine, built around the super-flexible Raspberry Pi.
Beat the banks, find the best exchange rates and avoid fees when you send money abroad from Australia.
All the key info you need to know to sell shares you inherited or received as a gift.
Steps to owning and managing Roblox shares.
Steps to owning and managing Zebit shares.
Steps to owning and managing CleanSpace shares.
Steps to owning and managing Benz Mining shares.